GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies.

@article{Robak2009GA101AT,
  title={GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies.},
  author={Tadeusz Robak},
  journal={Current opinion in investigational drugs},
  year={2009},
  volume={10 6},
  pages={588-96}
}
  • Tadeusz Robak
  • Published 2009 in Current opinion in investigational drugs
Glycart Biotechnology AG, Genentech Inc, F Hoffmann-La Roche Ltd, Biogen Idec Inc and Chugai Pharmaceutical Co Ltd are developing GA-101, a third-generation, humanized and glyco-engineered anti-CD20 IgG1 mAb, for the potential treatment of B-cell malignancies. Compared with classic type I CD20 antibodies (eg, rituximab), GA-101 binds with high affinity to the CD20 type II epitope, resulting in the induction of antibody-dependent cytotoxicity that is 5- to 100-fold greater than observed upon… CONTINUE READING

From This Paper

Topics from this paper.
40 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 40 extracted citations

Similar Papers

Loading similar papers…